Elevation Oncology Reports Initial Data From Dose Escalation Portion Of Ongoing Phase 1 Clinical Trial Of EO-3021; 42.8% Confirmed ORR Observed In Claudin 18.2-enriched Subset Of Gastric And GEJ Cancer
Portfolio Pulse from Benzinga Newsdesk
Elevation Oncology has reported initial data from the dose escalation portion of its ongoing Phase 1 clinical trial of EO-3021. The trial showed a 42.8% confirmed objective response rate (ORR) in a subset of patients with Claudin 18.2-enriched gastric and GEJ cancer. The company observed minimal MMAE-associated toxicities and plans to advance into monotherapy dose expansion and combination cohorts, with additional data expected in the first half of 2025.
August 06, 2024 | 11:18 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Elevation Oncology's initial data from the Phase 1 trial of EO-3021 shows a 42.8% ORR in Claudin 18.2-enriched gastric and GEJ cancer, with minimal toxicities. The company plans to advance into monotherapy dose expansion and combination cohorts, with more data expected in H1 2025.
The positive initial data from the Phase 1 trial, including a 42.8% ORR and minimal toxicities, is likely to boost investor confidence in Elevation Oncology. The planned advancements and future data releases could further drive stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100